[A13-25] Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
|Commission:||Commission awarded on 2013-06-14 by the Federal Joint Committee (G-BA)|
|Current document:||Dossier assessment Further documents|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|Contact address:||to the contact form|
Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
Extract of dossier assessment
Federal Joint Committee (G-BA)
2013-12-05 A G-BA decision was published.